1. Home
  2. QUBT vs NUVB Comparison

QUBT vs NUVB Comparison

Compare QUBT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum Computing Inc.

QUBT

Quantum Computing Inc.

HOLD

Current Price

$12.34

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$9.55

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUBT
NUVB
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
2.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QUBT
NUVB
Price
$12.34
$9.55
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$17.00
$10.63
AVG Volume (30 Days)
18.3M
6.8M
Earning Date
11-14-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$546,000.00
$26,748,000.00
Revenue This Year
$135.36
$609.55
Revenue Next Year
$373.64
$197.91
P/E Ratio
N/A
N/A
Revenue Growth
41.45
1137.19
52 Week Low
$4.37
$1.54
52 Week High
$25.84
$9.53

Technical Indicators

Market Signals
Indicator
QUBT
NUVB
Relative Strength Index (RSI) 50.86 75.33
Support Level $10.13 $8.13
Resistance Level $11.42 $8.95
Average True Range (ATR) 1.04 0.53
MACD 0.06 0.01
Stochastic Oscillator 62.96 90.68

Price Performance

Historical Comparison
QUBT
NUVB

About QUBT Quantum Computing Inc.

Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: